Six-part educational initiative aims to help community oncologists navigate the growing complexity of CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates
The International Myeloma Society (IMS) is launching its new U.S. Community Webinar Series, “IMS Community Webinar Series: Optimizing the use of ADCs and TCRTs,” a six-part virtual educational initiative designed to help community oncology providers better understand and implement emerging immune-based therapies for patients with multiple myeloma.
As immune-based therapies such as CAR-T cell therapies, bispecific antibodies/T-cell engagers and antibody-drug conjugates (ADCs) continue to rapidly reshape the treatment landscape for multiple myeloma, IMS leaders say many community oncology providers remain early in the adoption curve due to the complexity of treatment selection, toxicity management, and referral coordination. The webinar series aims to bridge the gap by providing practical, clinically focused education for oncologists, hematologists, advanced practice providers, nurses and pharmacists practicing outside major academic treatment centers.
‘Immune-based therapies are rapidly transforming the treatment landscape for multiple myeloma, but many community oncology providers are still navigating how to safely and effectively integrate these highly specialized therapies into routine practice,’
said Noopur S. Raje, Director for the Center of Multiple Myeloma and Secretary at the International Myeloma Society.
‘Because the vast majority of patients receive care outside major academic centers, it is critical that we equip community physicians with practical guidance around treatment selection, toxicity management, referral coordination and long-term patient monitoring so more patients can benefit from these advances.’
Because only a relatively small percentage of physicians specialize specifically in myeloma care, many patients receive treatment in broader community oncology settings – underscoring the urgent need for expanded education, collaboration and practical guidance as advanced immunotherapies become more widely available.
According to IMS, while several T-cell redirection therapies and BCMA-targeted therapies are already approved and increasingly used in relapsed/refractory multiple myeloma, experience with these therapies remains uneven across community settings. The series is designed to provide real-world guidance around patient selection, therapy sequencing, management of cytokine release syndrome (CRS) and neurotoxicity, referral pathways and long-term toxicity monitoring.
The webinars will feature leading myeloma experts from across the United States and include case-based discussions, practical implementation guidance and open panel discussions focused on challenges community providers may encounter when incorporating these therapies into practice.
‘The pace of innovation in myeloma has created tremendous opportunity for patients, but it has also reinforced the importance of stronger collaboration across the oncology community,’
said Dr. Nikhil Munshi, Immediate Past President of the International Myeloma Society.
‘By bringing together leading myeloma specialists and community providers in a practical, discussion-driven format, this series is intended to help accelerate knowledge-sharing and support more consistent access to emerging therapies across care settings.’
The webinar series schedule includes:
- June 24, 2026 (East U.S.)
- July 15, 2026 (Central U.S.)
- July 29, 2026 (West U.S.)
- August 6, 2026 (East U.S.)
- August 20, 2026 (Central U.S.)
- August 27, 2026 (West U.S.)
Featured faculty throughout the series include internationally recognized myeloma experts from leading institutions including Dana-Farber Cancer Institute, Mayo Clinic, Mount Sinai Medical Center, Memorial Sloan Kettering Cancer Center, UCSF and MD Anderson Cancer Center, among others. Faculty participants include Noopur Raje, Shaji Kumar, Nikhil Munshi, Sundar Jagannath, Saad Usmani, Ajai Chari, Thomas Martin, Krina Patel, Adriana Rossi, and others.
Topics throughout the series will include:
- Challenges and barriers to T-cell redirection therapies
- Clinical use of antibody-drug conjugates (ADCs)
- Bispecific antibody therapies
- CAR-T cell therapies
- Toxicity management and patient monitoring
- Practical implementation in community oncology settings
Registration for the complimentary webinar series is now open. For more information and to register, please visit.
About the International Myeloma Society (IMS)
The International Myeloma Society is the only global society focused on Myeloma research and clinical care. The non-profit organization is committed to improving outcomes for myeloma patients through scientific exchange, education, advocacy, and research. Representing thousands of experts across more than 60 countries, IMS convenes the world’s foremost myeloma scientists to accelerate cures, foster collaboration, and transform patient care. The organization places a specific emphasis on funding research (with $15.64 Million Provided), advancing access to clinical care and Myeloma research in low-to-middle income countries, and creating opportunities for early career researchers.
You can also read:
Smoldering Multiple Myeloma (SMM) in Transition: The Role of Early Intervention
